Merck reported Phase 3 results for sacituzumab tirumotecan (sacituzumab tirumotecan, or sac-TMT) in advanced endometrial cancer, describing a one-third reduction in the risk of death versus control. The targeted chemotherapy is already approved in China through Kelun, and Merck is running 18 global Phase 3 studies intended to support regulatory filings across the US and Europe. The update adds to the evidence base for ADC-style approaches in women’s cancers, particularly in settings where standard options can deliver limited durability. For industry stakeholders, the program’s scale—multiple concurrent Phase 3 efforts—signals Merck’s push to replace revenue as key oncology assets approach patent cliffs. Near-term developments for the field include how Merck positions sac-TMT relative to competing ADC and immunotherapy strategies and how safety profiles translate in larger, diverse populations.